Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline

Informazioni relative al progetto

RespiriNTM

ID dell’accordo di sovvenzione: 853932

DOI

10.3030/853932

Data della firma CE 8 Maggio 2019

Data di avvio 1 Maggio 2019

Data di completamento 30 Aprile 2027

Finanziato da

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Costo totale

€ 16 009 225,82

Contributo UE

€ 5 687 983,75

Coordinato da

ACADEMISCH ZIEKENHUIS LEIDEN
Netherlands

CORDIS fornisce collegamenti ai risultati finali pubblici e alle pubblicazioni dei progetti ORIZZONTE.

I link ai risultati e alle pubblicazioni dei progetti del 7° PQ, così come i link ad alcuni tipi di risultati specifici come dataset e software, sono recuperati dinamicamente da .OpenAIRE .

Risultati finali

Documents, reports (6)

In vitro activity of single HDT compounds report

In vitro activity of single HDT compounds report will summarize the results of in vitro activity of single Host Directed Therapeutics compounds against intracellular NTM strains in human cells

Zebrafish in vivo test report

The Zebrafish in vivo test report will summarize the methodology and results of the efficacy against known tuberculosis compounds and the effect on granuloma testing in zebrafish larvae for individual NTM compounds

Human NTM in vitro infection Model report

The Human NTM in vitro infection Model report will describe the methodology and assay conditions for an in vitro infection model for NTM (M. avium) in human cells

Purified NTM cytochrome report

The Purified NTM cytochrome report will describe the methodology and confirmation of the biological structures of the purified cytochrome bc1, bc1:aa3, and bd

NTM drug PK report

NTM drug PK report will describe the methodology used and describe the PK model of the NTM drugs

Enzymatic Assay and Characterization of cyt bc1 & bd inhibitors report

The Enzymatic Assay and Characterization of cyt bc1 & bd inhibitors report will describe the assay, conditions and characterisation methodology of the enzymatic assay for testing cytochrome bc1 and cytochrome bd inhibitors

Websites, patent fillings, videos etc. (1)

Website RESPIRI- NTM online

The website developped for communication of all RespiriNTM activities will be active and online

Pubblicazioni

Peer reviewed articles (5)

Specificity of the innate immune responses to different classes of non-tuberculous mycobacteria

Autori: Wanbin Hu, Bjørn E. V. Koch, Gerda E. M. Lamers, Gabriel Forn-Cuní, Herman P. Spaink
Pubblicato in: Frontiers in Immunology, 2023, ISSN 1664-3224
Editore: Frontiers Media S.A
DOI: 10.3389/fimmu.2022.1075473

Modeling nontuberculous mycobacterial infections in zebrafish

Autori: Matt D. Johansen Herman P. Spaink Stefan H. Oehlers Laurent Kremer
Pubblicato in: Trends in Microbiology, 2023, ISSN 1878-4380
Editore: Cell Press
DOI: 10.1016/j.tim.2023.11.011

Host- directed therapy to combat mycobacterial infections

Autori: Gül Kilinç, Anno Saris, Tom H. M. Ottenhoff, Mariëlle C. Haks
Pubblicato in: Immunological Reviews, Numero 01052896, 2021, Pagina/e 62-83, ISSN 0105-2896
Editore: Blackwell Publishing Inc.
DOI: 10.1111/imr.12951

Development of Human Cell-Based In Vitro Infection Models to Determine the Intracellular Survival of Mycobacterium avium

Autori: Gül Kilinç, Kimberley V. Walburg, Kees L. M. C. Franken, Merel L. Valkenburg, Alexandra Aubry, Mariëlle C. Haks, Anno Saris1, Tom H. M. Ottenhoff
Pubblicato in: Frontiers in Cellular and Infection Microbiology, 2022, ISSN 2235-2988
Editore: Frontiers Media S. A.
DOI: 10.3389/fcimb.2022.872361

Host-directed therapy with amiodarone in preclinical models restricts mycobacterial infection and enhances autophagy

Autori: Gül Kilinç, Ralf Boland, Matthias T. Heemskerk, Herman P. Spaink, Mariëlle C. Haks, Michiel van der Vaart, Tom H. M. Ottenhoff, Annemarie H. Meijer, Anno Saris
Pubblicato in: Microbiology Spectrum, Numero 12, 2024, ISSN 2165-0497
Editore: American Society for Microbiology
DOI: 10.1128/spectrum.00167-24